Your browser doesn't support javascript.
loading
Acceptance of COVID-19 vaccination at different hypothetical efficacy and safety levels in ten countries in Asia, Africa, and South America.
Rosiello, Dott F; Anwar, Samsul; Yufika, Amanda; Adam, Rashed Y; Ismaeil, Mohajer Ih; Ismail, Asma Y; Dahman, Nesrine Bh; Hafsi, Montacer; Ferjani, Manel; Sami, Farah S; Monib, Fatma A; Subramaniam, R; Anandu, Sunil; Haque, Md Ariful; Ferreto, Lirane Ed; Aburto, José To; Rojas, Jorge Et; Enitan, Seyi S; Yomi, Akele R; Ezigbo, Eyiuche D; Babadi, Elham; Kakemam, Edris; Malik, Najma I; Ullah, Irfan; Sallam, Malik.
Afiliação
  • Rosiello DF; Department of Public Health and Infectious Disease, Sapienza-University of Rome, Rome, Italy.
  • Anwar S; Department of Statistics, Faculty of Mathematics and Natural Sciences, Universitas Syiah Kuala, Banda Aceh, Indonesia.
  • Yufika A; Department of Family Medicine, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia.
  • Adam RY; Omdurman Teaching Hospital, Khartoum, Sudan.
  • Ismaeil MI; Faculty of Medicine, Alzaiem Alazhari University, Khartoum, Sudan.
  • Ismail AY; Department of Internal Medicine, Faculty of Medicine, Sudan International University, Khartoum, Sudan.
  • Dahman NB; Faculty of Medicine of Tunis, University of Tunis El Manar, Tunisia.
  • Hafsi M; Faculty of Medicine of Tunis, University of Tunis El Manar, Tunisia.
  • Ferjani M; Faculty of Medicine of Tunis, University of Tunis El Manar, Tunisia.
  • Sami FS; Faculty of Medicine, Ain Shams University, Nasr City, Cairo, Egypt.
  • Monib FA; Faculty of Medicine, Assiut University, Assiut, Egypt.
  • Subramaniam R; Department of Public Health Dentistry, Indira Gandhi Institute of Dental Sciences, Nellikuzhi, Kothamangalam, Kerala, India.
  • Anandu S; Division of Veterinary Parasitology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India.
  • Haque MA; Department of Orthopedic Surgery, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.
  • Ferreto LE; Department of Public Health and Postgraduate Program in Applied Health Sciences, Faculty of Medicine, Western Paraná State University, Brazil.
  • Aburto JT; Faculty of Medicine, University of La Frontera, Temuco, Chile.
  • Rojas JE; Faculty of Medicine, University of La Frontera, Temuco, Chile.
  • Enitan SS; Department of Medical Laboratory Science, Babcock University, Ilishan-Remo, Ogun State, Nigeria.
  • Yomi AR; Department of Medical Laboratory Science, Afe Babalola University, Ado Ekiti, Nigeria.
  • Ezigbo ED; Department of Medical Laboratory Sciences, Faculty of Health Sciences & Technology University of Nigeria, Enugu State Nigeria.
  • Babadi E; Research Fellow, Mayo Clinic, Rochester, USA.
  • Kakemam E; Iranian Center of Excellence in Health Management, School of Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Malik NI; Department of Psychology, University of Sargodha, Sargodha, Pakistan.
  • Ullah I; Department of Internal Medicine, Kabir Medical College, Gandhara University, Peshawar, Pakistan.
  • Sallam M; Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, The University of Jordan, Amman Jordan.
Narra J ; 1(3): e55, 2021 Dec.
Article em En | MEDLINE | ID: mdl-38450212
ABSTRACT
Vaccine hesitancy, defined as the reluctance or rejection in receiving a vaccine despite its availability, represents a major challenge to global health efforts aiming to control the ongoing COVID-19 pandemic. Understanding the possible factors correlated with COVID-19 vaccine hesitancy using a refined well-informed approach can be helpful to address the phenomenon. The current study aimed to evaluate COVID-19 vaccine acceptance rates using four hypothetical scenarios of varying levels of vaccine efficacy and safety profiles in ten Asian, African and South American countries. These scenarios included 95% efficacy and 20% side effects (Vaccine A), 75% efficacy and 5% side effects (Vaccine B); 75% efficacy and 20% side effects (Vaccine C) and 50% efficacy and 5% side effects (Vaccine D). This study used a self-administered online survey that was distributed during February-May 2021. The total number of study respondents was 1337 with countries of residence as follows India (21.1%), Pakistan (12.9%), Sudan (11.2%), Nigeria (9.3%), Iran (8.2%), Bangladesh and Brazil (7.9%), Chile (7.7%), Tunisia (7.6%), and Egypt (6.2%). The overall acceptance rates for COVID-19 vaccination were variable based on varying degrees of safety and efficacy as follows 55.6% for Vaccine C, 58.3% for Vaccine D, 74.0% for Vaccine A and 80.1% for Vaccine B. The highest levels of COVID-19 vaccine acceptance were observed in Brazil followed by Chile across the four different safety and efficacy scenarios. The lowest COVID-19 vaccine acceptance rates were reported in Egypt and Tunisia for the low safety scenarios (20% side effects), and the low efficacy scenario (50% efficacy). The study revealed the potential effect of vaccine safety and efficacy on the intention to get COVID-19 vaccination. At the same efficacy level, higher possibility of side effects caused a large drop in COVID-19 vaccine acceptance rate. This indicates the importance of accurate communication regarding vaccine safety and efficacy on attitude towards the vaccine and intentions to get vaccinated. Regional differences in COVID-19 vaccine acceptance were observed with the Middle East/North African countries showing the lowest rates and the South American countries displaying the highest vaccine acceptance rates.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Narra J Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Narra J Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália